SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gómez, E. Articles by Löwenberg, B. Search for Related Content PubMed PubMed Citation Articles by Gómez, E. Articles by Löwenberg, B. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 91 No. 6 (March 15), 1998: pp. 2208-2209 CORRESPONDENCE Rapid Simultaneous Screening of Factor V Leiden and G20210A Prothrombin Variant by Multiplex Polymerase Chain Reaction on Whole Blood     LETTER To the Editor: The mutation in factor V (FV) G1691A, known as factor V Leiden,1 and the recently described genetic variation in the prothrombin (FII) gene G20210A2 are the two most prevalent known causes of inherited thrombophilia. Several polymerase chain reaction (PCR)-based methods have been described for the detection of each of them, separately. Although PCR is technically easy, it is rather expensive and time-consuming; the rate-limiting step is usually the DNA isolation. These arguments are important when considering the cost-benefit of large-scale prophylactic testing in individuals at risk. PCR amplification of FV Leiden from whole blood has been reported to be feasible and reliable.3,4 In addition, a method for the combined detection of both abnormalities by using purified DNA has been recently published.5 An ideal method would be the combination of both advantages, ie, a multiplex PCR for the simultaneous detection of both genetic abnormalities using whole blood as DNA source. We report here a very rapid, simple, and cost-saving method for the genotypic diagnosis of both risk factors. This is achieved by multiplex PCR amplification of the involved region of both genes using whole blood as DNA source, followed by combined restriction digestion and agarose gel electrophoresis. First, we compared the feasibility of multiplex amplifications on purified DNA using conditions for FII (Poort et al2 and R.M. Bertina, personal communication, December 1996) and FV1 with minor modifications. Despite the different conditions, both gene products were amplified using either of these two methods. However, the FII program gave stronger amplifications (not shown). FII amplifications were performed using 67 mmol/L Tris-HCl, pH 8.8; 16.6 mmol/L (NH4)2SO4; 6.7 mmol/L MgCl2; 10 mmol/L 2-mercaptoethanol; 100 µg/mL bovine serum albumin; 10% dimethylsulphoxide; 1.5 mmol/L of each dNTP; 2.5 U Taq DNA polymerase (Amplitaq; Perkin Elmer Cetus, Norwalk, CT); 500 ng of each FII; and 400 ng of each FV primer1,2 in a total volume of 50 µL. The sequence of the reverse FV primer (5-CTTGAAGGAAATGCCCCATTA-3) is different from that described.1 The FII program we use is as follows: After a denaturation step at 95°C for 4 minutes, thermal cycling was 1 minute of denaturing at 94°C, 1 minute of annealing at 53°C, and 2 minutes of extension at 67°C, with cycles repeated 32 times. Subsequently, different amounts of whole blood (0.5, 1.0, 2.0, 5.0, and 10.0 µL) were assayed by adding ddH2O up to 20 µL before denaturation. The samples were denatured by heating the blood at 95°C for 5 minutes and then cooling at 30°C for 30 seconds, which was repeated three times. When using 1.0 or 2.0 µL of whole blood, both gene products were amplified using either the FII or the FV program. Again, the FII program resulted in stronger amplifications as compared with the FV program (Fig 1, lanes 1 and 2). Occasionally, low yields were obtained when using program FII. Therefore, we increased the number of cycles from 32 to 40. Because this resulted in consistent high yields (Fig 1, lane 3), we favor the use of 40 cycles for the multiplex amplification. Identical results were obtained when either fresh or frozen blood was used. When using half or one quarter of the amount of each of the primers, the yields were significantly lower (not shown). View larger version (72K): [in this window] [in a new window]   Fig 1. Multiplex detection of wild-type and mutated FII (G20210A) and FV (G1691A) using whole blood (2 µL) as the DNA source in PCR. Lanes 1 through 3, undigested multiplex PCR products using the described conditions for FII (lane 1 [32 cycles] and 3 [40 cycles]) and for FV (lane 2). Lanes 4 through 9, undigested and Mnl I and HindIII double-digested PCR product electrophoresis of a patient double heterozygote for FII and FV; undigested and digested factor FV fragment (lanes 4 and 5, respectively); undigested and digested FII fragment (lanes 6 and 7, respectively); undigested and digested FII and FV fragments obtained after multiplex PCR (lanes 8 and 9, respectively). Lanes 10 through 13, double-digested products obtained after multiplex PCR from a normal individual (lane 10), an FII and FV Leiden double heterozygote (lane 11), an FII heterozygote (lane 12), and an FV Leiden heterozygote (lane 13). Products were separated on a 2.5% agarose gel (per lane, 20 µL of the digestion mix is loaded). Marker is a 100-bp size marker (GIBCO BRL, Grand Island, NY). Relevant fragment sizes in basepairs are indicated. For the genotype analysis, the 220-bp FV and 345-bp FII PCR products obtained by multiplex PCR were simultaneously digested by adding 6 U Mnl I and 10 U HindIII (New England Biolabs, Beverley, MA) to 28 µL of PCR product, incubated for 2 hours at 37°C, and subsequently separated on agarose gel. The wild-type FII fragment contains two Mnl I sites but no HindIII sites, resulting in fragments of 15, 58, and 272 bp, whereas the 20210A (mutated) product contains two Mnl I sites and one HindIII site, resulting in fragments of 15, 23, 58, and 249 bp after double digestion. The FV fragment contains no HindIII sites, resulting in Mnl I fragments of 37, 67, and 116 bp for the wild-type allele and 67 and 153 bp for the mutated allele. Consequently, when both PCR products of a patient double heterozygote for FII and FV are digested, fragments of 272, 249, 153, and 116 bp are detected (Fig 1, lanes 9 and 11). In conclusion, the presented multiplex amplification on 2 µL of whole blood followed by a combined restriction digest of the obtained PCR products offers a very rapid, feasible, and cost-saving method for large-scale FII and FV genotype analysis. Encarnación Gómez Sonja C.P.A.M. van der Poel Joop H. Jansen Bert A. van der Reijden Bob Löwenberg Department of Hematology University Hospital Dijkzigt Institute of Hematology Erasmus University Rotterdam, The Netherlands        REFERENCES 1. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, Van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64, 1994[Medline] [Order article via Infotrieve] 2. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698, 1996[Abstract/Free Full Text] 3. Rees DC, Cox M, Clegg JB: Detection of the factor V Leiden mutation using whole blood PCR. Thromb Haemost 75:520, 1995 4. Corral J, Iniesta JA, Gonzáles-Conjero R, Vicente V: Detection of factor V Leiden from a drop of blood. Thromb Haemost 76:735, 1996[Medline] [Order article via Infotrieve] 5. Ripoll L, Paulin D, Thomas S, Drouet O: Multiplex PCR-mediated site-directed mutagenesis for one-step determination of factor V Leiden and G20210A transition of the prothrombin gene. Thromb Haemost 90:960, 1997 © 1998 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. J. van Stralen, F. R. Rosendaal, and C. J. M. Doggen Minor Injuries as a Risk Factor for Venous Thrombosis Arch Intern Med, January 14, 2008; 168(1): 21 - 26. [Abstract] [Full Text] [PDF] N. Abramson, J. P. Costantino, J. E. Garber, N. Berliner, D. L. Wickerham, and N. Wolmark Effect of Factor V Leiden and Prothrombin G20210->A Mutations on Thromboembolic Risk in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst, July 5, 2006; 98(13): 904 - 910. [Abstract] [Full Text] [PDF] J. W. Blom, C. J. M. Doggen, S. Osanto, and F. R. Rosendaal Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis JAMA, February 9, 2005; 293(6): 715 - 722. [Abstract] [Full Text] [PDF] G. Endler, P. A. Kyrle, S. Eichinger, M. Exner, and C. Mannhalter Multiplexed Mutagenically Separated PCR: Simultaneous Single-Tube Detection of the Factor V R506Q (G1691A), the Prothrombin G20210A, and the Methylenetetrahydrofolate Reductase A223V (C677T) Variants Clin. Chem., February 1, 2001; 47(2): 333 - 335. [Full Text] [PDF] S. Huber, K. J. McMaster, and K. V. Voelkerding Analytical Evaluation of Primer Engineered Multiplex Polymerase Chain Reaction-Restriction Fragment Length Polymorphism for Detection of Factor V Leiden and Prothrombin G20210A J. Mol. Diagn., August 1, 2000; 2(3): 153 - 157. [Abstract] [Full Text] F. A.J.T.M. van den Bergh, A. M. van Oeveren-Dybicz, and M. A.M. Bon Rapid Single-Tube Genotyping of the Factor V Leiden and Prothrombin Mutations by Real-Time PCR Using Dual-Color Detection Clin. Chem., August 1, 2000; 46(8): 1191 - 1195. [Full Text] [PDF] G. Muriel, B. Christine, J. Philippe, M. Christophe, S. J. Francois, and A. M. Patricia An Even Easier Method for One-Step Detection of Both FV Leiden and FII G20210A Transition Blood, November 1, 1998; 92(9): 3478 - 3479. [Full Text] [PDF] This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gómez, E. Articles by Löwenberg, B. Search for Related Content PubMed PubMed Citation Articles by Gómez, E. Articles by Löwenberg, B. Social Bookmarking                   What's this?

	Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020